Form 4: Inovio Pharmaceuticals CFO Peter Kies Reports Stock Transactions

CFO Peter Kies reports the vesting of restricted stock units and subsequent tax withholding by Inovio Pharmaceuticals.

Summary

• On May 15, 2024, Peter Kies, CFO of Inovio Pharmaceuticals, had 4,771 restricted stock units vest.
• These units were settled, resulting in the acquisition of 4,771 shares of common stock.
• The company withheld 2,562 shares to cover Kies' tax obligations at a price of $13.07 per share.
• Following these transactions, Kies directly owns 24,367 shares and indirectly owns 375 shares through his spouse.
• The reported transactions give effect to a 1-for-12 reverse stock split that occurred on January 24, 2024.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't indicate any significant positive or negative sentiment.

Future Outlook

The vesting schedule includes future vesting dates of May 15, 2025, and May 15, 2026, for 4,771 shares each.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and are closely monitored by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning management's interests with those of shareholders.
• Tax withholding practices related to vesting are standard across publicly traded companies.
• The size of the holdings and transactions are typical for a CFO of a company of Inovio's size.

Stakeholder Impact

• The vesting of restricted stock units and subsequent tax withholding are standard components of executive compensation and should have minimal impact on stakeholders.

Key Dates